Wen-bo Yu

12 Middle Wulumuqi Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model.

GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model.

Journal: Neuropharmacology

Published: May 14, 2025

Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts.

Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: September 28, 2024

The homozygous LRRK2.p.N1437D point mutation mouse is a novel model of parkinsonism.

The homozygous LRRK2.p.N1437D point mutation mouse is a novel model of parkinsonism.

Journal: NPJ Parkinson's disease

Published: April 23, 2024

Bidirectional interaction between IL and 17A/IL-17RA pathway dysregulation and α-synuclein in the pathogenesis of Parkinson's disease.

Bidirectional interaction between IL and 17A/IL-17RA pathway dysregulation and α-synuclein in the pathogenesis of Parkinson's disease.

Journal: Brain, behavior, and immunity

Published: March 28, 2024

Corrigendum: Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson's disease with a deep learning algorithm.

Corrigendum: Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson's disease with a deep learning algorithm.

Journal: Frontiers in pharmacology

Published: December 03, 2022

Cellular and Molecular Mechanisms Underly the Combined Treatment of Fasudil and Bone Marrow Derived-Neuronal Stem Cells in a Parkinson's Disease Mouse Model.

Cellular and Molecular Mechanisms Underly the Combined Treatment of Fasudil and Bone Marrow Derived-Neuronal Stem Cells in a Parkinson's Disease Mouse Model.

Journal: Molecular neurobiology

Published: August 04, 2022

Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson's disease.

Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson's disease.

Journal: Frontiers in pharmacology

Published: July 30, 2022

Discovery of styrylaniline derivatives as novel alpha-synuclein aggregates ligands.

Discovery of styrylaniline derivatives as novel alpha-synuclein aggregates ligands.

Journal: European journal of medicinal chemistry

Published: August 23, 2021

Disease progression in Parkinson's disease patients with subjective cognitive complaint.

Disease progression in Parkinson's disease patients with subjective cognitive complaint.

Journal: Annals of clinical and translational neurology

Published: July 06, 2021

Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy.

Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: January 26, 2021

Quality of Life in Newly Diagnosed Patients With Parkin-Related Parkinson's Disease.

Quality of Life in Newly Diagnosed Patients With Parkin-Related Parkinson's Disease.

Journal: Frontiers in neurology

Published: July 07, 2020

Eomesodermin in CD4+T cells is essential for Ginkgolide K ameliorating disease progression in experimental autoimmune encephalomyelitis.

Eomesodermin in CD4+T cells is essential for Ginkgolide K ameliorating disease progression in experimental autoimmune encephalomyelitis.

Journal: International journal of biological sciences

Published: July 03, 2020

Showing 1-12 of 28

Last Updated: 09/26/2026